SYGNIS Announces Global Launch of the Second Kit from its TruePrime(TM) Product Line: TruePrime(TM) WGA Kit

SYGNIS AG / Key word(s): Market launch

2015-02-23 / 08:00


Press Release

SYGNIS Announces Global Launch of the Second Kit from its TruePrime(TM) Product Line: TruePrime(TM) WGA Kit

SYGNIS is further executing on its product and commercialization strategy

TruePrime(TM) WGA Kit is superior to common standards in WGA

Product available through distribution partners and TruePrime(TM) online shop

Madrid, Spain and Heidelberg, Germany, February 23th, 2015 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced the global launch of TruePrime(TM) WGA kit, the second product of its TruePrime(TM) product line for whole genome amplification (WGA).

SYGNIS TruePrime(TM) product family covers a series of kits for whole genome amplification based on SYGNIS’ proprietary revolutionary TruePrime(TM) technology, processing multiple displacement amplification (MDA) for use with various DNA or RNA species from a variety of samples for a multitude of applications.

Based on the combination of SYGNIS’ recently discovered DNA primase TthPrimPol with its Phi29 polymerase, SYGNIS’ TruePrime(TM) technology stands for a revolution in the way DNA or RNA are amplified from a sample. While the current standard technologies in WGA need short pieces of DNA (“oligonucleotides”) to start the reaction, the TruePrime(TM) technology does not need any synthetic random primers at all.

/

Like SYGNIS’ first product dedicated for the amplification of DNA from single cells, the new product for the amplification of entire genomes from various sample types and smaller volumes shows outstanding capabilities including the complete absence of common artifacts linked to the use of oligonucleotides, a reduced amplification bias in genome coverage compared to methods using random synthetic primers, a surpassing reliability as the technology is insensitive to external DNA contaminations and a high reproducibility. In addition, TruePrime(TM) WGA Kit shows superior sensitivity, is easy to use and works perfectly well with all commonly used NGS platforms such as Illumina and Ion Torrent.

The superior features of the TruePrime(TM) WGA Kit make this product highly attractive for a wide range of applications and downstream analyses in all areas where researchers are working with limited sample volumes but do not need to obtain DNA from individual cells such as in human genetics, personalized medicine, oncology, diagnostics and pathology, to name just a few.

“We are very proud and excited about the launch of our second kit from our TruePrime(TM) product line for whole genome amplification,” Pilar de la Huerta, CEO and CFO of SYGNIS commented. “With this second product launch within just four weeks and the various distribution agreements we recently signed for Europe and North America, we are strongly executing on our product and commercialization strategy. We are committed to sustaining this strong momentum and will continue to further expand our portfolio with highly innovative products.”

The TruePrime(TM) WGA kit is in stock and will be globally commercialized mainly through distributors as well as through SYGNIS’ own TruePrime(TM) online shop under www.sygnis.com/shop. TruePrime(TM) WGA Kit is available in two formats, containing 25 or 100 reactions.

SYGNIS has started an extensive promotional mailing campaign to all potential users in the molecular biology field. The Company plans a wide range of additional marketing events around the product launch including presentations at key international scientific meetings and conferences including the currently held US Advances in Genome Biology and Technologies (AGBT) meeting and the American Association of Cancer Research (AACR) annual meeting in March, to name just two. In addition the company will organize a special TruePrime(TM) webinar in March hosted by the inventor of this technology and scientific board member of SYGNIS, Prof. Luis Blanco.

SYGNIS is currently developing a series of additional TruePrime(TM) kits for a variety of applications that are expected to be launched throughout 2015.

About TruePrime(TM)

TruePrime(TM) is the brand name of a revolutionary novel MDA technology and one of the key products in SYGNIS’ portfolio. TruePrime(TM) is based on the combination of the recently discovered DNA primase “TthPrimPol” and the extremely processive and high-fidelity Phi29 polymerase to amplify uniformly total genomic DNA for a multitude of applications including next generation sequencing and single cell analysis. The extraordinary strand displacement capacity of the Phi29 polymerase allows TthPrimPol to generate new primers on the displaced strands that are extended by Phi29 DNA pol, resulting in exponential isothermal DNA amplification without the need of any synthetic random primers.

For further information please contact:

SYGNIS AG
Pilar de la Huerta
CEO/CFO
Phone: +34 91 192 36 50
Email: pdelahuerta@sygnis.com
 
MC Services AG
Raimund Gabriel
Managing Partner
Phone: +49 89 210228 30
Email: raimund.gabriel@mc-services.eu

About SYGNIS AG: www.sygnis.com

Following the merger with X-Pol Biotech in 2012, SYGNIS specializes on the development and commercialization of products for DNA amplification and sequencing. SYGNIS AG, listed at the German Stock Exchange (Prime Standard segment, Tick: LIO1; ISIN: DE000A1RFM03), has a commercial product for whole genome DNA amplification, SensiPhi(R), licensed to an industry leading partner and is currently developing its own TruePrime(TM) product line based on its proprietary TruePrime(TM) technology for use in the fast growing field of Next Generation Sequencing. The first product for single cell DNA amplification was launched in January 2015.

### Disclaimer

This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason.###


2015-02-23 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de



325763  2015-02-23